Search results
Q3 2024 Earnings Forecast for Merck & Co., Inc. Issued By Leerink Partnrs (NYSE:MRK)
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Free Report) – Research analysts at Leerink Partnrs raised their Q3 2024 earnings per share estimates for Merck & Co., Inc ...
Merck beats earnings expectations, raises outlook on strong Keytruda and vaccine sales
CNBC· 3 days agoMerck on Thursday reported first-quarter revenue and adjusted earnings that topped expectations as...
Merck raises 2024 profit forecast on strong sales of cancer drug Keytruda
Reuters via AOL· 3 days ago(Reuters) -Merck & Co on Thursday raised its annual profit and revenue forecast on the back of...
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Zacks· 3 days agoFree Report) reported adjusted earnings of $2.07 per share for first-quarter 2024, beating the Zacks Consensus Estimate of $1.94. Earnings rose 48% year over year on a reported basis and 54% ...
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 4 days agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...
Merck&Co earnings beat by $0.14, revenue topped estimates
Investing.com· 3 days agoMerck&Co earnings beat by $0.14, revenue topped estimates
Merck (MRK) Q1 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 2 days agoImage source: The Motley Fool. Merck (NYSE: MRK) Q1 2024 Earnings Call Apr 25, 2024, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
Merck Beats on Earnings a Month After Major Drug Approval. The Stock Is Rising.
Barrons.com· 3 days agoFEATURE Sales of Merck ‘s blockbuster cancer drug Keytruda jumped 20% in the first quarter of the...
Merck & Co., Inc. (NYSE:MRK) is a favorite amongst institutional investors who own 78%
Simply Wall St. via Yahoo Finance· 7 days agoKey Insights Given the large stake in the stock by institutions,Merck's stock price might be...
Analysts Set Merck & Co., Inc. (NYSE:MRK) Price Target at $131.25
ETF DAILY NEWS· 6 days agoMerck & Co., Inc. (NYSE:MRK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock ...
